#### provided by I-Revues

# Atlas of Genetics and Cytogenetics in Oncology and Haematology



**OPEN ACCESS JOURNAL** 

INIST-CNRS

## **Gene Section**

**Short Communication** 

## CXXC5 (CXXC finger protein 5)

## Pelin Yasar, Mesut Muyan

Department of Biological Sciences, Middle East Technical University, Ankara, Turkey (PY, MM)

Published in Atlas Database: April 2014

Online updated version: http://AtlasGeneticsOncology.org/Genes/CXXC5ID52549ch5q31.html

DOI: 10.4267/2042/55369

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2015 Atlas of Genetics and Cytogenetics in Oncology and Haematology

## **Abstract**

Review on CXXC5, with data on DNA/RNA, on the protein encoded and where the gene is implicated.

## Identity

Other names: CF5, RINF, WID HGNC (Hugo): CXXC5

Location: 5q31.2

Local order: From centromere to telomere:

SPATA24-DNAJC18-ECSCR-TMEM173-

UBE2D2-CXXC5-PSD2-NRG2. **Note:** Orientation on forward strand.

## DNA/RNA

## Description

The gene is on the plus strand and encompasses 35 kb of DNA.


The exon number of gene is 3 and parts of the second and third exons encode the protein (ENSP00000302543).

## Transcription


1447 bp long mRNA; 969 bp long open reading frame.

## Pseudogene


No reported pseudogenes.



Local order of CXXC5 is shown together with leading and subsequent genes on chromosome 5. The direction of arrows indicates transcriptional directions on the chromosome and arrow sizes approximate gene sizes.



Boxes are exons. The lines are introns. Shaded parts of the exon boxes are coding regions. Unshaded parts are noncoding regions.



CXXC5 contains a nuclear localization signal adjacent to the CXXC-zinc finger domain.

## **Protein**

## Description

CXXC5 encodes a 322 amino-acid protein with a molecular mass of 33 kDa. Amino-acid sequence suggests that CXXC5 contains a number of phosphorylation and acetylation sites.

By homology, CXXC5 is considered to be a member of CXXC-type zinc finger protein family, which binds to non-methylated CpG dinuclotide containing DNA.

## **Expression**

CXXC5 is expressed in various tissues.

## Localisation

CXXC5 protein is mainly in the nucleus. CXXC5 protein may also be localized in the cytoplasm coupled with Dishevelled (Dvl) protein (Andersson et al., 2009).

#### **Function**

CXXC5 can be induced by retinoid signaling and is required for myelopoiesis (Pendino et al., 2009). CXXC5 protein is involved in the DNA-damage induced p53 activation as well as in the regulation of cell cycle and apoptosis (Zhang et al., 2009). CXXC5 protein participates in the TNF-a-induced apoptosis through association with SMAD (Wang et al., 2013).

CXXC5 protein is a critical modulator of BMP4-regulated Wnt-signaling in neural stem cells (Andersson et al., 2009).

CXXC5 protein is shown to repress TET2 gene expression (Ko et al., 2013).

## Homology

CXXC domain is a highly conserved domain of a class of proteins that interact with non-methylated CpG dinucleotides (CpGs). The CXXC domain of CXXC5 displays a significant homology to CXXC domains of CXXC4 and TET3 proteins (Ko et al., 2013).

## **Mutations**

Note

Not defined yet.

## Implicated in

# Acute myeloid leukemia (AML) and Myelodysplastic syndrome (MDS)

#### Disease

Acute myeloid leukemia (AML) is a disease manifested by cytogenetic anomalies affecting cell proliferation, death and differentiation (Renneville et al., 2008). Myelodysplastic syndrome (MDS) defines a hematological condition with insufficient hematopoiesis. MDS results from chromosomal deletions, inversions and translocations giving rise to trilineage dysplasia (Mhawech and Saleem, 2001).

## **Oncogenesis**

The region on the chromosome 5 which also contains CXXC5 gene (5q31.2) is often deleted in AML and MDS (Treppendahl et al., 2013). Low survival rate has been observed in intensive chemotherapy treated patients with AML who show a high level of CXXC5 gene expression (Astori et al., 2013).

## Acute promyelocytic leukemia (APL)

#### Disease

APL, which is characterized by the translocation event of the retinoic acid receptor alpha gene, is a rare subtype of AML in which leukemia cells are sensitive to anthracyclines (Tallman and Altman, 2008).

### Oncogenesis

Terminal maturation of premyelocytic leukemia cells requires the expression of CXXC5 (Pendino et al., 2009).

### Breast cancer

#### Disease

Breast cancer is a disease which is mainly originated in the lining of the milk ducts and/or the lobules.

#### **Oncogenesis**

It has been shown that CXXC5 is transcriptionally upregulated in some solid tumors including

melanoma, thyroid and breast cancer. In addition, overexpression of CXXC5 in breast cancer is suggested to be associated with poor prognosis (Knappskog et al., 2011).

## References

Mhawech P, Saleem A. Myelodysplastic syndrome: review of the cytogenetic and molecular data. Crit Rev Oncol Hematol. 2001 Dec;40(3):229-38

Tallman MS, Altman JK. Curative strategies in acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program. 2008;:391-9

Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, Preudhomme C. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008 May;22(5):915-31

Andersson T, Södersten E, Duckworth JK, Cascante A, Fritz N, Sacchetti P, Cervenka I, Bryja V, Hermanson O. CXXC5 is a novel BMP4-regulated modulator of Wnt signaling in neural stem cells. J Biol Chem. 2009 Feb 6;284(6):3672-81

Pendino F, Nguyen E, Jonassen I, Dysvik B, Azouz A, Lanotte M, Ségal-Bendirdjian E, Lillehaug JR. Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis. Blood. 2009 Apr 2;113(14):3172-81

ZHANG M, WANG R, WANG Y, DIAO F, LU F, GAO D, CHEN D, ZHAI Z, SHU H. The CXXC finger 5 protein is required for DNA damage-induced p53 activation. Sci China C Life Sci. 2009 Jun;52(6):528-38

Knappskog S, Myklebust LM, Busch C, Aloysius T, Varhaug JE, Lønning PE, Lillehaug JR, Pendino F. RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer. Ann Oncol. 2011 Oct;22(10):2208-15

Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud Ø. CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia. Oncotarget. 2013 Sep;4(9):1438-48

Ko M, An J, Bandukwala HS, Chavez L, Aijö T, Pastor WA, Segal MF, Li H, Koh KP, Lähdesmäki H, Hogan PG, Aravind L, Rao A. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature. 2013 May 2;497(7447):122-6

Treppendahl MB, Möllgård L, Hellström-Lindberg E, Cloos P, Grønbaek K. Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q. Eur J Haematol. 2013 Mar;90(3):259-60

Wang X, Liao P, Fan X, Wan Y, Wang Y, Li Y, Jiang Z, Ye X, Mo X, Ocorr K, Deng Y, Wu X, Yuan W. CXXC5 Associates with Smads to Mediate TNF- $\alpha$  Induced Apoptosis. Curr Mol Med. 2013 Sep;13(8):1385-96

This article should be referenced as such:

Yasar P, Muyan M. CXXC5 (CXXC finger protein 5). Atlas Genet Cytogenet Oncol Haematol. 2015; 19(1):1-3.